Rituximab and IVIG added to plasma exchange improves the outcome of severe CNS demyelinating attacks: a retrospective study

Juan Luis Chico-Garcia, Moisés Morales de la Prida, Almudena Boix Lago, José Manuel García-Domínguez, María Sepúlveda, Eugenia Martínez-Hernández, Mar Guasp, Elianet Fonseca, Alberto Calvi, María Teresa Alba-Isasi, Blanca Albertí, Joan Cid, Miquel Lozano, Paola Charry, Fernando Rodríguez-Jorge, Raquel Sainz-Amo, Susana Sainz de la Maza, Enric Monreal, Luisa Maria Villar, Jaime Masjuan, Gabriel Valero-López, Jorge Millán-Pascual, Juan Pablo Cuello, Michael Palacios, Ariadna Gifreu Fraixinó, María Luisa Martínez-Gins, Gary Álvarez Bravo, José E. Meca-Lallana, Lucienne Costa-Frossard, Yolanda Blanco, Jose Maria Cabrera-Maqueda, Albert Saiz, Sara Llufriu

Therapeutic Advances in Neurological Disorders

Published online on May 08, 2026

Abstract

Therapeutic Advances in Neurological Disorders, Volume 19, January-December 2026.
Background:Plasma exchange (PE) is a therapeutic option for CNS demyelinating attacks unresponsive to corticosteroids, but the potential benefit of adding rituximab and IV immunoglobulins to PE (RTX-IVIG-PE), which has shown its efficacy and safety in ...